SEARCH

SEARCH BY CITATION

References

  • 1
    Howard L, Heaphey L, Fleming CR, Lininger L, Steiger E. Four years of North American registry home parenteral nutrition outcome data and their implications for patient management. JPEN J Parenter Enteral Nutr 1991; 15(4): 38493.
  • 2
    Weser E. Nutritional aspects of malabsorption: short gut adaptation. Clin Gastroenterol 1983; 12: 443.
  • 3
    Fone DR, Horowitz M, Read NW, Dent J, Maddox A. The effect of terminal ileal triglyceride infusion on gastroduodenal motility and the intragastric distribution of a solid meal. Gastroenterology 1990; 98: 56875.
  • 4
    Spiller RC, Trotman IF, Higgins BE et al. The ileal brake-inhibition of jejunal motility after ileal fat perfusion in man. Gut 1984; 25: 36574.
  • 5
    Van Clitters GW, Lin HC. The ileal brake: a fifteen-year progress report. Curr Gastroenterol Rep 1999; 1(5): 4049.
  • 6
    Rouill’e Y, Westermark G, Martin SK, Steiner DF. Proglucagon is processed to glucagon by prohormone convertase PC2 in αTC1-6 cells. Proc Natl Acad Sci USA 1994; 91: 32426.
  • 7
    Brubaker PL. The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis. Ann N Y Acad Sci 2006; 1070: 1026.
  • 8
    Kazberouk AD, Giovinazzo F, Timberlake A et al. Mechanisms of crosstalk between intestinal EC and L cells: the roles of serotonin and glucagon-like peptide 1 in regulating neuroendocrine cell function. Gastroenterology 2010; 138(5): S4034.
  • 9
    Schmidt T, Pfeiffer A, Hackelsberger N et al. Effect of intestinal resection on human small bowel motility. Gut 1996; 38: 85963.
  • 10
    Mikhail N. Exenatide: a novel approach for treatment of type 2 diabetes. South Med J 2006; 99(11): 12719.
  • 11
    Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005; 143(8): 55969.
  • 12
    Gallwitz B. New therapeutic strategies for the treatment of type 2 diabetes based on incretins. Rev Diabet Stud 2005; 2(2): 619.
  • 13
    Nauck MA, Niedereichholz U, Ettler R et al. Glucagon-like peptide-1 inhibition of gastric emptying outweighs its insulinotrophic effects in healthy humans. Am J Physiol 1997; 1: E9819.
  • 14
    Nauck MA. Is glucagon-like peptide 1 an incretin hormone? Diabetologia 1999; 42(3): 3739.
  • 15
    Ritzel R, Orskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers, dose-response-relationships. Diabetologia 1995; 38(6): 7205.
  • 16
    Edwards CBM, Todd JF, Ghatei MA et al. Subcutaneous glucagon-like peptide-I (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects. Clin Sci 1998; 96: 71924.
  • 17
    Drucker DJ. Biologic actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002; 122(2): 53144.
  • 18
    Jeppeson PB. Glucagon-like peptide-2: update of the recent clinical trials. Gastroenterology 2006; 130(2): S12731.
  • 19
    Iakoubov R, Lauffer LM, Trivedi S et al. Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology 2009; 150(9): 403343.
  • 20
    Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214(3): 82935.
  • 21
    Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004; 12: 86776.